EA201691478A1 - Новый полисахарид и его применения - Google Patents
Новый полисахарид и его примененияInfo
- Publication number
- EA201691478A1 EA201691478A1 EA201691478A EA201691478A EA201691478A1 EA 201691478 A1 EA201691478 A1 EA 201691478A1 EA 201691478 A EA201691478 A EA 201691478A EA 201691478 A EA201691478 A EA 201691478A EA 201691478 A1 EA201691478 A1 EA 201691478A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bioconjugates
- compositions
- coli
- host cells
- document
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0066—Isolation or extraction of proteoglycans from organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
В данном документе предложен новый О-полисахарид Е. coli. - O25В. В данном документе также предложены прокариотические клетки-хозяева, содержащие ферменты (например гликозилтрансферазы), используемые в получении O25В. Клетки-хозяева, предложенные здесь, продуцируют биоконъюгаты O25В, которые содержат O25В, связанный с белком-носителем. Кроме того, здесь предложены композиции, например фармацевтические композиции, содержащие O25В, и/или биоконъюгаты, содержащие O25В. Такие композиции могут быть использованы в качестве вакцин против инфекции ЕхРЕС (внекишечные патогенные Е. coli) и могут дополнительно содержать один или более дополнительных биоконъюгатов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943710P | 2014-02-24 | 2014-02-24 | |
PCT/EP2015/053739 WO2015124769A1 (en) | 2014-02-24 | 2015-02-23 | Novel polysaccharide and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201691478A1 true EA201691478A1 (ru) | 2017-02-28 |
EA035991B1 EA035991B1 (ru) | 2020-09-10 |
EA035991B9 EA035991B9 (ru) | 2020-10-21 |
Family
ID=52589386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691478A EA035991B9 (ru) | 2014-02-24 | 2015-02-23 | Новый полисахарид и его применения |
Country Status (21)
Country | Link |
---|---|
US (5) | US9700612B2 (ru) |
EP (1) | EP3110441B1 (ru) |
JP (2) | JP6276427B2 (ru) |
KR (1) | KR101855142B1 (ru) |
CN (1) | CN106535927B (ru) |
AR (1) | AR100859A1 (ru) |
AU (1) | AU2015220723C1 (ru) |
CA (1) | CA2940547C (ru) |
CL (1) | CL2016002123A1 (ru) |
DK (1) | DK3110441T3 (ru) |
EA (1) | EA035991B9 (ru) |
FI (1) | FI3110441T3 (ru) |
IL (1) | IL247344B (ru) |
LT (1) | LT3110441T (ru) |
MX (1) | MX2016011055A (ru) |
NZ (1) | NZ723328A (ru) |
PH (1) | PH12016501671A1 (ru) |
PT (1) | PT3110441T (ru) |
SG (1) | SG11201606889PA (ru) |
TW (1) | TWI639439B (ru) |
WO (1) | WO2015124769A1 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014111516A1 (en) | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
FI3110441T3 (fi) | 2014-02-24 | 2024-05-06 | Glaxosmithkline Biologicals Sa | Uusi polysakkaridi ja sen käyttöjä |
US10722580B2 (en) * | 2015-05-13 | 2020-07-28 | University Of Washington | Compositions and methods for treatment and prevention of uropathogenic E. coli infection |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711637D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2019175147A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against intra-abdominal infections |
CN108531439B (zh) * | 2018-04-16 | 2020-04-07 | 南京工业大学 | 一种大肠杆菌基因工程菌及其构建方法与应用 |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
JP2022525773A (ja) | 2019-03-18 | 2022-05-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 大腸菌o抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法 |
MX2021011445A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. |
CN110018253A (zh) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业(浙江)有限公司 | 一种生物制品中游离蛋白含量的高效液相测定方法 |
CN111855826B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理(中国)有限公司 | 破伤风类毒素或白喉类毒素的监测方法 |
GB201908528D0 (en) * | 2019-06-13 | 2019-07-31 | Univ Dundee | Rhamnose-polysaccharides |
CA3168108A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
WO2021255684A1 (en) | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
CA3185642A1 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Modified exotoxin a proteins |
CN115803087A (zh) | 2020-09-17 | 2023-03-14 | 杨森制药公司 | 多价疫苗组合物及其用途 |
IL301880A (en) | 2020-11-30 | 2023-06-01 | Janssen Pharmaceuticals Inc | Analytical method for glycoconjugation using a capillary-based immunoassay system |
MX2023008251A (es) | 2021-01-12 | 2023-07-26 | Janssen Pharmaceuticals Inc | Mutantes de fimh, composiciones con estos y uso de estos. |
US20240131135A1 (en) | 2021-02-16 | 2024-04-25 | Duke University | Vaccine compositions and methods for the treatment and prevention of urinary tract infections |
MX2023011697A (es) | 2021-04-01 | 2023-10-19 | Janssen Pharmaceuticals Inc | Produccion de bioconjugados o18 de e. coli. |
CN117098550A (zh) | 2021-04-08 | 2023-11-21 | 杨森制药公司 | 生物缀合物生产方法 |
WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
US12014256B2 (en) * | 2022-01-12 | 2024-06-18 | Dell Products L.P | Polysaccharide archival storage |
CN114150005B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
EP1481057B1 (en) | 2002-03-07 | 2006-02-15 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
EP1888761B1 (en) | 2005-05-11 | 2010-09-29 | ETH Zurich | Recombinant n-glycosylated proteins from procaryotic cells |
WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
EP3427749A1 (en) | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
TR201803015T4 (tr) | 2009-11-19 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem. |
RU2013131795A (ru) | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
JP2014526449A (ja) * | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
US20150238596A1 (en) | 2012-09-10 | 2015-08-27 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
TR201904022T4 (tr) | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
JP2016501550A (ja) | 2012-12-27 | 2016-01-21 | グリコヴァキシン アーゲー | Crm197に関する方法及び組成物 |
WO2014111516A1 (en) * | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
SG11201602546RA (en) | 2013-10-11 | 2016-04-28 | Glycovaxyn Ag | Methods of host cell modification |
JP6590413B2 (ja) | 2014-02-06 | 2019-10-16 | エックスフォー・ファーマシューティカルズ(オーストリア)ゲーエムべーハー | 大腸菌特異的抗体配列 |
FI3110441T3 (fi) | 2014-02-24 | 2024-05-06 | Glaxosmithkline Biologicals Sa | Uusi polysakkaridi ja sen käyttöjä |
PT3240895T (pt) | 2014-12-30 | 2022-03-02 | Glaxosmithkline Biologicals Sa | Composições e métodos para glicosilação de proteínas |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
JP2022525773A (ja) | 2019-03-18 | 2022-05-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 大腸菌o抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法 |
MX2021011445A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. |
-
2015
- 2015-02-23 FI FIEP15706459.3T patent/FI3110441T3/fi active
- 2015-02-23 EP EP15706459.3A patent/EP3110441B1/en active Active
- 2015-02-23 CN CN201580020077.8A patent/CN106535927B/zh active Active
- 2015-02-23 NZ NZ723328A patent/NZ723328A/en unknown
- 2015-02-23 CA CA2940547A patent/CA2940547C/en active Active
- 2015-02-23 PT PT157064593T patent/PT3110441T/pt unknown
- 2015-02-23 DK DK15706459.3T patent/DK3110441T3/da active
- 2015-02-23 US US14/628,844 patent/US9700612B2/en active Active
- 2015-02-23 KR KR1020167026424A patent/KR101855142B1/ko active IP Right Grant
- 2015-02-23 LT LTEPPCT/EP2015/053739T patent/LT3110441T/lt unknown
- 2015-02-23 AR ARP150100534A patent/AR100859A1/es unknown
- 2015-02-23 SG SG11201606889PA patent/SG11201606889PA/en unknown
- 2015-02-23 JP JP2016570184A patent/JP6276427B2/ja active Active
- 2015-02-23 WO PCT/EP2015/053739 patent/WO2015124769A1/en active Application Filing
- 2015-02-23 EA EA201691478A patent/EA035991B9/ru unknown
- 2015-02-23 AU AU2015220723A patent/AU2015220723C1/en active Active
- 2015-02-23 MX MX2016011055A patent/MX2016011055A/es unknown
- 2015-02-24 TW TW104105953A patent/TWI639439B/zh active
-
2016
- 2016-08-18 IL IL247344A patent/IL247344B/en active IP Right Grant
- 2016-08-23 CL CL2016002123A patent/CL2016002123A1/es unknown
- 2016-08-23 PH PH12016501671A patent/PH12016501671A1/en unknown
-
2017
- 2017-07-07 US US15/643,788 patent/US10441647B2/en active Active
-
2018
- 2018-01-11 JP JP2018002276A patent/JP6771499B2/ja active Active
-
2019
- 2019-10-11 US US16/599,900 patent/US10940192B2/en active Active
-
2021
- 2021-02-02 US US17/165,333 patent/US11738076B2/en active Active
-
2023
- 2023-04-24 US US18/305,948 patent/US20230364214A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691478A1 (ru) | Новый полисахарид и его применения | |
BR112018070187A2 (pt) | receptores quiméricos para flt3 e seus métodos de uso | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
MX2016014807A (es) | Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados. | |
AR105464A1 (es) | Composiciones probióticas secas estables para usos dietarios especiales | |
BR112019007803A2 (pt) | formulações de vacina de glicoconjugado contra expec | |
CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
TN2015000411A1 (en) | Ceftolozane antibiotic compositions | |
EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
CA3010667A1 (en) | Use of 4-bora-3a,4a-diaza-s-indacenes for security purposes | |
BR112015011697A2 (pt) | antibióticos macrocíclicos de amplo espectro | |
EA201891577A1 (ru) | Системы и способы для приготовления тромбоцитов | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
PH12017500450A1 (en) | Flavivirus virus like particle | |
EP4241851A3 (en) | Immunogenic compositions | |
PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
MX2023011670A (es) | Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). | |
EP4226936A3 (en) | Non-neuroinvasive viruses and uses thereof | |
EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
PL404229A1 (pl) | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie | |
EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
AR106716A1 (es) | Anticuerpos anti-factor d y conjugados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent |